Share on StockTwits

Investment analysts at Leerink Swann hoisted their price target on shares of Humana (NYSE:HUM) from $140.00 to $150.00 in a note issued to investors on Friday. The firm currently has an “outperform” rating on the stock. Leerink Swann’s price objective suggests a potential upside of 18.04% from the stock’s previous close.

Shares of Humana (NYSE:HUM) traded up 0.31% during mid-day trading on Friday, hitting $127.47. 223,038 shares of the company’s stock traded hands. Humana has a 1-year low of $83.73 and a 1-year high of $130.42. The stock has a 50-day moving average of $126.2 and a 200-day moving average of $111.9. The company has a market cap of $19.730 billion and a price-to-earnings ratio of 17.87.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $2.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.94 by $0.41. During the same quarter in the prior year, the company posted $2.69 earnings per share. On average, analysts predict that Humana will post $7.84 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on HUM. Analysts at Sterne Agee initiated coverage on shares of Humana in a research note on Friday, June 27th. They set a “neutral” rating and a $139.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Humana in a research note on Thursday, June 19th. They now have a $131.00 price target on the stock. Finally, analysts at Stifel Nicolaus upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. They now have a $155.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $125.50.

Humana Inc (NYSE:HUM) is a health care company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.